These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1139 related articles for article (PubMed ID: 20819978)

  • 1. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
    Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
    Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
    Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
    Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; Schmidt BL
    J Psychopharmacol; 2016 Dec; 30(12):1165-1180. PubMed ID: 27909164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
    Bogenschutz MP; Forcehimes AA; Pommy JA; Wilcox CE; Barbosa PC; Strassman RJ
    J Psychopharmacol; 2015 Mar; 29(3):289-99. PubMed ID: 25586396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
    Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
    Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.
    Bhagavan C; Glue P; Evans W; Reynolds L; Turner T; King C; Russell BR; Morunga E; Mills JL; Layton G; Menkes DB
    Trials; 2024 May; 25(1):336. PubMed ID: 38773523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
    Moreno FA; Wiegand CB; Taitano EK; Delgado PL
    J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
    Agin-Liebes GI; Malone T; Yalch MM; Mennenga SE; Ponté KL; Guss J; Bossis AP; Grigsby J; Fischer S; Ross S
    J Psychopharmacol; 2020 Feb; 34(2):155-166. PubMed ID: 31916890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Therapeutic Effects of Psilocybin.
    Johnson MW; Griffiths RR
    Neurotherapeutics; 2017 Jul; 14(3):734-740. PubMed ID: 28585222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
    White CM; Weisman N; Dalo J
    Ann Pharmacother; 2023 Sep; 57(9):1062-1075. PubMed ID: 36635883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of psilocybin-facilitated smoking cessation.
    Johnson MW; Garcia-Romeu A; Griffiths RR
    Am J Drug Alcohol Abuse; 2017 Jan; 43(1):55-60. PubMed ID: 27441452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
    Bogenschutz MP; Ross S; Bhatt S; Baron T; Forcehimes AA; Laska E; Mennenga SE; O'Donnell K; Owens LT; Podrebarac S; Rotrosen J; Tonigan JS; Worth L
    JAMA Psychiatry; 2022 Oct; 79(10):953-962. PubMed ID: 36001306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.
    Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL
    Psychopharmacology (Berl); 2018 Feb; 235(2):459-466. PubMed ID: 29085980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.